Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide

Pancreas. 2020 Mar;49(3):e19-e20. doi: 10.1097/MPA.0000000000001514.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Capecitabine / administration & dosage*
  • Female
  • Humans
  • Insulin / blood*
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Pancreatic Neoplasms / blood
  • Pancreatic Neoplasms / diagnostic imaging
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Peptides, Cyclic / administration & dosage*
  • Remission Induction
  • Secretory Pathway
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*
  • Temozolomide / administration & dosage*
  • Treatment Outcome
  • Vipoma / blood
  • Vipoma / diagnostic imaging
  • Vipoma / drug therapy*
  • Vipoma / secondary

Substances

  • Insulin
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Capecitabine
  • Temozolomide